In response to the COVID-19 situation, OCLI is following enhanced safety protocols consistent with guidelines put forth by the CDC and the World Health Organization (WHO) to protect our patients and colleagues. Click here to learn about how we are keeping you safe.

Avastin vs Lucentis: Genentech Co-Pay Card Program Not Nearly Enough!

November 14, 2009

I received an e-mail this week from Genentech BioOncology, introducing their new Co-Pay Card Program.  Genentech is the maker of the two drugs I have blogged about involved in the current macular degeneration treatment controversy, Lucentis and Acastin.

According to the e-mail:

“We are committed to ensuring that all eligible patients have access to the therapies they need. That is why we created the Genentech BioOncology Co-Pay Card Program, a program that gives eligible patients help with their BioOncology product co-pay.

This program will basically pay the 20% co-pay for those patients that financially qualify.  I think this is wonderful for certain treatment modalities, but not so in the case of Lucentis to treat macular degeneration.  The co-pay would be around $400.  What a nice gesture, what great marketing…  In my opinion, this is a joke.  What Genentech should be doing is seeking approval for the treatment of macular degeneration with Avastin!  Then let the patient handle the $10 co-pay themselves!!  Shame on you Genentech, hiding behind charity where corporate profits are the real issue!

Download Genentech Co-Pay Card Program

Back to our blog

Services offered at OCLI

Our world-class team of professionals at OCLI can help you with the latest treatment options for you.

Request an appointment

* required